Updates are available Correction dated 2025-05-27
Click to view Correction: https://doi.org/10.1038/s41598-025-02916-w
-
Authors
Thiyagarajan, Arulmani https://orcid.org/0000-0002-0413-1599
Koenen, Niklas https://orcid.org/0000-0002-4623-8271
Ittermann, Till https://orcid.org/0000-0002-0154-7353
Völzke, Henry https://orcid.org/0000-0001-7003-399X
Haug, Ulrike https://orcid.org/0000-0002-1886-2923
-
Funding
Funding for this research was provided by:
Universität Bremen
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 25 October 2024
First Online: 4 November 2024
Change Date: 27 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-025-02916-w
Declarations
:
: AT, NK and UH are working at an independent, non-profit research institute, the Leibniz Institute for Prevention Research and Epidemiology – BIPS. Unrelated to this study, BIPS occasionally conducts studies financed by the pharmaceutical industry. Almost exclusively, these are post-authorization safety studies (PASS) requested by health authorities. The design and conduct of these studies as well as the interpretation and publication are not influenced by the pharmaceutical industry. The study presented was not funded by the pharmaceutical industry and was performed in line with the ENCePP Code of Conduct. TI and HV have no conflict of interest to disclose.
: In terms of ethics approval, the Ethics Committee of the University of Bremen stated that studies based on GePaRD are exempt from institutional review board review. Apart from this, it is required to obtain approval from health insurance providers and their governmental authorities when using health insurance data for scientific purposes. The utilization of health insurance data for scientific research is regulated by the Code of Social Law in Germany. All involved health insurance providers as well as the German Federal Office for Social Security and the Senator for Health, Women and Consumer Protection in Bremen as their responsible authorities approved the use of GePaRD data for this study. According to the § 75 of the Code of Social Law X, informed consent for studies based on health insurance data is required by law unless obtaining consent appears unacceptable and would bias results. For this study, the responsible authorities approved the use of the data without informed consent as informed consent was deemed to be unacceptable and to bias results. The study was performed according to the institutional guidelines of the Leibniz Institute for Prevention Research and Epidemiology – BIPS as well as the “Good Practice in Secondary Data Analysis (GPS)” guideline (Third Revision 2012/2014).
